X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs WOCKHARDT LTD. - Comparison Results

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE WOCKHARDT LTD. SUVEN LIFE/
WOCKHARDT LTD.
 
P/E (TTM) x 19.2 -15.8 - View Chart
P/BV x 3.6 2.6 137.3% View Chart
Dividend Yield % 1.1 1.3 82.8%  

Financials

 SUVEN LIFE   WOCKHARDT LTD.
EQUITY SHARE DATA
    SUVEN LIFE
Mar-16
WOCKHARDT LTD.
Mar-17
SUVEN LIFE/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs3391,129 30.0%   
Low Rs144627 23.0%   
Sales per share (Unadj.) Rs39.2363.1 10.8%  
Earnings per share (Unadj.) Rs7.5-20.4 -36.5%  
Cash flow per share (Unadj.) Rs8.8-7.0 -125.8%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.81.1 72.7%  
Book value per share (Unadj.) Rs49.0301.8 16.2%  
Shares outstanding (eoy) m127.28110.55 115.1%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x6.22.4 254.5%   
Avg P/E ratio x32.4-42.9 -75.4%  
P/CF ratio (eoy) x27.5-125.9 -21.9%  
Price / Book Value ratio x4.92.9 169.4%  
Dividend payout %26.8-48.9 -54.8%   
Avg Mkt Cap Rs m30,73297,063 31.7%   
No. of employees `0001.06.8 14.1%   
Total wages/salary Rs m4169,665 4.3%   
Avg. sales/employee Rs Th5,236.15,931.8 88.3%   
Avg. wages/employee Rs Th436.51,428.1 30.6%   
Avg. net profit/employee Rs Th995.5-334.0 -298.1%   
INCOME DATA
Net Sales Rs m4,99540,146 12.4%  
Other income Rs m1941,143 16.9%   
Total revenues Rs m5,18941,289 12.6%   
Gross profit Rs m1,233128 963.0%  
Depreciation Rs m1671,489 11.2%   
Interest Rs m542,253 2.4%   
Profit before tax Rs m1,205-2,472 -48.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m255-211 -120.8%   
Profit after tax Rs m950-2,260 -42.0%  
Gross profit margin %24.70.3 7,739.3%  
Effective tax rate %21.28.5 247.8%   
Net profit margin %19.0-5.6 -337.7%  
BALANCE SHEET DATA
Current assets Rs m4,98646,160 10.8%   
Current liabilities Rs m1,04219,258 5.4%   
Net working cap to sales %79.067.0 117.8%  
Current ratio x4.82.4 199.6%  
Inventory Days Days61101 60.5%  
Debtors Days Days3994 41.6%  
Net fixed assets Rs m3,12640,165 7.8%   
Share capital Rs m127553 23.0%   
"Free" reserves Rs m3,71732,814 11.3%   
Net worth Rs m6,23633,367 18.7%   
Long term debt Rs m43231,903 1.4%   
Total assets Rs m8,07989,687 9.0%  
Interest coverage x23.2-0.1 -23,913.8%   
Debt to equity ratio x0.11.0 7.3%  
Sales to assets ratio x0.60.4 138.1%   
Return on assets %12.40 -144,730.6%  
Return on equity %15.2-6.8 -224.8%  
Return on capital %18.9-0.3 -5,631.4%  
Exports to sales %87.50-   
Imports to sales %12.20-   
Exports (fob) Rs m4,371NA-   
Imports (cif) Rs m611NA-   
Fx inflow Rs m4,6669,121 51.2%   
Fx outflow Rs m9422,133 44.2%   
Net fx Rs m3,7246,988 53.3%   
CASH FLOW
From Operations Rs m922-2,695 -34.2%  
From Investments Rs m-619-6,863 9.0%  
From Financial Activity Rs m-69812,545 -5.6%  
Net Cashflow Rs m-3963,010 -13.1%  

Share Holding

Indian Promoters % 63.4 74.5 85.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 2.3 -  
FIIs % 0.0 7.7 -  
ADR/GDR % 0.0 0.1 -  
Free float % 36.5 15.4 237.0%  
Shareholders   37,287 67,757 55.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare SUVEN LIFE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Feb 23, 2018 (Close)

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUVEN LIFE WITH

MARKET STATS